DIA Product, News Roundup
Almac’s New Clinical Supply Chain Value-AddTheorem Clinical Research Debuts New BrandingHealthcare Businesswomen’s Association and DIA Form Leadership InitiativeVodafone, Exco InTouch Partners in Patient Reported Outcomes and Patient EngagementPhlexglobal Re-Brands Around TMF ExpertisePAREXEL MyTrials Fully Integrated eClinical Workflow SolutionPharmaNet/i3’s New IRT Release for Randomization, SupplyOracle’s New Version for Translational ResearchDrugDev Survey on Study Start-Up, Site IdentificationTrifecta Multimedical, Web-based Investigator TrainingNew Name, Brand for Clinical Financial ServicesOpen SafeGuard Manages Social Platforms for Potential RiskIntraLinks’ Second Year Global Investigator Site SurveyQuanticate Launches Next Generation Functional Service ProvisionBBK Worldwide Launches Online Patient Recruitment Purchasing PowerMerge eClinical OS, Clinical Trial Operating SolutionComprehend Systems, Analytics in the CloudY-Prime’s Content Review Publishing Tool
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
